Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/26/2013US20130344077 Monoclonal antibodies
12/26/2013US20130344065 Combination Treatment with VEGF-C Antagonists
12/26/2013US20130344061 Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors
12/26/2013US20130344056 Keratin biomaterials for treatment of ischemia
12/26/2013US20130344051 Compostion of matter for treating or preventing various types of cancer and neoplastic diseases in a mammal
12/26/2013US20130344040 Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
12/26/2013US20130344032 Method of Treating Anemia Caused By Ribavirin Treatment of Hepatitis C Using Erythropoietin Alpha
12/26/2013US20130344031 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
12/26/2013US20130344028 1'-substituted carba-nucleoside analogs for antiviral treatment
12/26/2013US20130344027 Multi-functional polymeric materials and their uses
12/26/2013US20130344024 Co-Therapy for Diabetic Conditions
12/26/2013US20130344014 Therapeutic vitamin d sun-protecting formulations and methods for their use
12/26/2013US20130344011 Reduction Of Tooth Staining Derived From Cationic Antimicrobials
12/26/2013US20130344007 Frankincense chewing gum
12/26/2013US20130344005 Bolus for treating hypocalcaemia in ruminants
12/26/2013US20130344000 Treatment of cognitive impairment in a subject with a neurological autoimmune disease
12/26/2013US20130343998 Control and Characterization of Memory Function
12/26/2013US20130343996 Graphite-coated magnetic nanoparticles
12/26/2013US20130343988 Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer
12/26/2013US20130343987 Myocardial perfusion imaging methods and compositions
12/26/2013CA2831054A1 Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
12/25/2013EP2677031A1 Kinases as targets for anti-diabetic therapy
12/25/2013EP2676965A1 Aryl glycoside compound, preparation method and use thereof
12/25/2013EP2676961A1 Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
12/25/2013EP2676960A1 Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
12/25/2013EP2676959A1 Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
12/25/2013EP2676958A1 N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
12/25/2013EP2676957A1 Tosylate Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
12/25/2013EP2676956A1 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
12/25/2013EP2676955A1 Thiazole Derivative and use thereof as VAP-1 Inhibitor
12/25/2013EP2676954A1 Heterocyclyl-substituted-phenyl derivatives as vasodilators
12/25/2013EP2676953A1 Hemifumarate Salt and Medical Indications
12/25/2013EP2676952A2 Preparation method and crystalline form IV of optical enantiomers of modafinil
12/25/2013EP2676678A1 Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof
12/25/2013EP2676667A1 Polyethylene glycol colonic purgative composition
12/25/2013EP2676666A1 Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
12/25/2013EP2676665A1 Use of -mangostin in preparation of medicaments for treating alzheimer's disease
12/25/2013EP2676664A1 Potentiator of antitumor activity of chemotherapeutic agent
12/25/2013EP2676663A2 Transdermal delivery system containing galantamine or salts thereof
12/25/2013EP2676661A2 Orally administered sustained-release triple-layer pill containing tamsulosin or pharmaceutically acceptable salt thereof
12/25/2013EP2676660A1 Compositions preventing hypertension comprising soluplus
12/25/2013EP2676658A1 Heat-sterilised injectable composition of hyaluronic acid, polyol(s) and lidocaine
12/25/2013EP2676142A1 Methods and compositions relating to coagulation assays
12/25/2013EP2675918A2 Compositions and methods for delivering nucleic acid to a cell
12/25/2013EP2675895A2 Molecular switch for neuronal outgrowth
12/25/2013EP2675822A1 Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
12/25/2013EP2675821A1 Pregnanolone derivatives substituted in 3alpha-position with the cationic group, method of their production, usage and pharmaceutical preparation involving them
12/25/2013EP2675814A1 Haprolid and derivatives thereof as inhibitors of hcv
12/25/2013EP2675813A1 Anti-thrombotic compounds
12/25/2013EP2675812A1 Chroman - spirocyclic piperidine amides as modulators of ion channels
12/25/2013EP2675811A1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
12/25/2013EP2675807A1 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d]pyrimidin- 4 - one derivatives their use as pde9a inhibitors
12/25/2013EP2675806A1 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
12/25/2013EP2675803A1 Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
12/25/2013EP2675802A1 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
12/25/2013EP2675801A1 Novel pyrazole and imidazole derivatives useful as orexin antagonists
12/25/2013EP2675798A1 Novel benzodioxole piperazine compounds
12/25/2013EP2675796A1 1,4-oxazepines as bace1 and/or bace2 inhibitors
12/25/2013EP2675795A1 Substituted aminobutyric derivatives as neprilysin inhibitors
12/25/2013EP2675794A1 Selective fak inhibitors
12/25/2013EP2675793A1 Fak inhibitors
12/25/2013EP2675792A1 Substituted aminobutyric derivatives as neprilysin inhibitors
12/25/2013EP2675791A1 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
12/25/2013EP2675790A1 Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of alzheimer's disease
12/25/2013EP2675788A1 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy
12/25/2013EP2675787A1 Aminoindane compounds and use thereof in treating pain
12/25/2013EP2675771A1 4-hydroxybutyric acid deuterated analogs
12/25/2013EP2675527A1 Veterinary anti-prolactin composition for ruminants
12/25/2013EP2675526A1 Novel sulfonaminoquinoline hepcidin antagonists
12/25/2013EP2675462A2 Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
12/25/2013EP2675461A1 Dietetic or pharmaceutical preparation containing tartary buckwheat
12/25/2013EP2675460A1 Treatment of submental fat
12/25/2013EP2675459A1 Compounds and methods of treating diabetes
12/25/2013EP2675458A1 Compounds and methods for treatment of hypertension
12/25/2013EP2675457A1 Pharmaceutical formulation for topical administration comprising b220
12/25/2013EP2675456A1 Methods for treating diseases of the retina
12/25/2013EP2675455A2 Ophthalmic composition for enabling dilation of pupils
12/25/2013EP2675454A1 Methods for controlling pain in equines using a transdermal solution of fentanyl
12/25/2013EP2675453A1 Methods for controlling pain in canines using a transdermal solution of fentanyl
12/25/2013EP2675452A1 Liquid propellant-free formulation comprising an antimuscarinic drug
12/25/2013EP2675451A1 mTOR/JAK INHIBITOR COMBINATION THERAPY
12/25/2013EP2675450A1 Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
12/25/2013EP2675449A1 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
12/25/2013EP2675448A1 Method of treating ischemia/reperfusion injury
12/25/2013EP2675447A2 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
12/25/2013EP2675446A1 Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
12/25/2013EP2675445A1 Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
12/25/2013EP2675444A1 A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
12/25/2013EP2675443A1 Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
12/25/2013EP2675442A1 Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
12/25/2013EP2675441A1 Compositions comprising peroxy alpha-ketocarboxylic acid and methods for producing and using the same
12/25/2013EP2675440A1 Cathepsin cysteine protease inhibitors
12/25/2013EP2675439A2 Combination of glycopyrrolate and a beta2 -agonist
12/25/2013EP2675438A1 Extended release powder and aqueous suspension comprising methylphenidate
12/25/2013EP2675437A1 Filmcoated solid dosage forms comprising honey in the coating
12/25/2013EP2675435A1 Sustained release composition of memantine
12/25/2013EP2675433A1 Absorbent dressings with painkilling activity
12/25/2013EP2675289A1 Water soluble nutritional compositions comprising cereal beta-glucan and resistant starch
12/25/2013EP2675278A1 Methods for synthesizing molybdopterin precursor z derivatives
12/25/2013EP2675276A1 PERIPHERIALLY ACTING µ OPIOID ANTAGONISTS
1 ... 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 ... 7860